Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
BMJ Open Respir Res
; 4(1): e000212, 2017.
Article
en En
| MEDLINE
| ID: mdl-29018526
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Guideline
/
Qualitative_research
Idioma:
En
Revista:
BMJ Open Respir Res
Año:
2017
Tipo del documento:
Article